JCR Pharma announces its domestic development plan for the Duchenne Muscular Dystrophy treatment drug givinostat, aiming to submit for approval within 2026 and to commence sales within 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4552-20260715-01.pdf","jir_short_summary":"JCR Pharma announces its domestic development plan for the Duchenne Muscular Dystrophy treatment drug givinostat, aiming to submit for approval within 2026 and to commence sales within 2027.","jir_summary":"### Performance Overview\nJCR Pharma is advancing the domestic development of the histone deacetylase (HDAC) inhibitor givinostat, planning to submit for manufacturing and sales approval within 2026 and aiming for sales launch within 2027. The drug has already been approved overseas, and clinical trials are progressing in Japan. The impact on this fiscal year's performance is expected to be minimal.\n\n### Future Outlook\nThe company aims to leverage overseas clinical data to develop strategies that deliver the treatment early to Japanese DMD patients. Toward approval and sales start in 2027, R&D will be promoted to provide new treatment options for unmet medical needs in DMD.","jir_financial_highlights":"Scheduled year for manufacturing and sales approval application for this drug: Within 2026 (Unknown)\nScheduled year for sales start: Within 2027 (Unknown)\nImpact on consolidated earnings for the current period (ending March 2027): Minimal (Unknown)","jir_category":"","jir_hashtags":"#JCRPharmaceutical, #FinancialResults, #JapanStocks","jir_key_figures":"Scheduled year for manufacturing and sales approval application for this drug: within 2026\nScheduled year for sales start: within 2027\nImpact on consolidated earnings for the current period (ending March 2027): minimal","jir_meta_title":"\u3010JCR Pharmaceutical\u3011Domestic Development Plan and Approval Outlook\uff5cJuly 2026","jir_meta_description":"JCR Pharma is advancing domestic development of a Duchenne Muscular Dystrophy treatment drug, planning to submit for approval in 2026 and start sales in 2027. The impact on this fiscal year is expected to be minimal.","jir_og_title":"\u3010JCR Pharmaceutical\u3011Domestic Development Plan and Approval Outlook\uff5cJuly 2026","jir_og_description":"JCR Pharma is promoting the domestic development of a muscular dystrophy treatment drug, with plans for approval in 2026 and sales start in 2027.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-81009","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n